Last reviewed · How we verify

Routine continuous cluster of Alutard SQ

Beijing Tongren Hospital · FDA-approved active Biologic

Alutard SQ is an allergen immunotherapy product that desensitizes patients to specific allergens through gradual dose escalation.

Alutard SQ is an allergen immunotherapy product that desensitizes patients to specific allergens through gradual dose escalation. Used for Allergic rhinitis and/or allergic asthma caused by specific allergens (e.g., pollen, dust mites, animal dander).

At a glance

Generic nameRoutine continuous cluster of Alutard SQ
SponsorBeijing Tongren Hospital
Drug classAllergen immunotherapy (subcutaneous immunotherapy, SCIT)
ModalityBiologic
Therapeutic areaAllergy/Immunology
PhaseFDA-approved

Mechanism of action

Alutard SQ works by administering increasing doses of allergen extract subcutaneously to induce immune tolerance. This process shifts the immune response from IgE-mediated (allergic) to IgG-mediated (protective) antibodies, and increases regulatory T cells, thereby reducing allergic symptoms upon natural allergen exposure.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results